

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/jtd-23-1408	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The prescription patterns of camrelizumab in the neoadjuvant therapy as well as the perioperative outcome of the patients will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	None
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date.
7	To whom will you share the data?	Medical oncologists.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of neoadjuvant therapy in esophageal squamous cell carcinoma patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: drzy01@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.